Burzynski Research Institute

Burzynski Research Institute, Inc. engages in the research, production, marketing, promotion, and sale of medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives, and organic acids under the trade name Antineoplastons. The company is headquartered in Houston, Texas and currently employs 0 full-time employees. The company went IPO on 2001-10-15. Antineoplastons are useful in the treatment of human cancer. The firm is reviewing data from its Phase II clinical trials of Antineoplastons relating to the treatment of various cancers. Antineoplastons are found in the bodily fluids of humans and food. The firm conducted all the Phase II clinical trials for the treatment of a variety of cancers using the combination of Antineoplastons A10 and AS2-1. Clinical trials conducted by the Company primarily use intravenous formulations of Antineoplastons, though few trials also use oral formulations. The firm's clinical trials are conducted at the Burzynski Clinic.